Skip To Main Content
Thomas Lamb on Muck Rack

Thomas Lamb

Wilmington
As seen in: PLOS, Respiratory Research, BioRxiv, DVIDS, eLife, WWAY-TV (Wilmington, NC), Newsfile Corp., The Messenger (Madisonville, KY), West Plains Daily Quill, Drug Injury Law
A lawyer representing people in drug injury lawsuits involving drug side effects and adverse reactions. For other types of legal cases, see @ThomasJLamb account
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Thomas

Contact Thomas, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Ozempic Eye Side Effect NAION Warnings Update July 2026

|
By Thomas Lamb
| Drug Injury Law
Non-arteritic anterior ischemic optic neuropathy (NAION) is an eye side effect associated with Ozempic in numerous medical reports over the past couple of years. This article provides an Ozempic eye side effect NAION warnings update as of late July 2026 covering the US and some other countries around the world.
Open in Who Shared Issue with article?

Semaglutide NAION Lawsuits in 2026 for Wegovy, Rybelsus, Ozempic Vision Loss

|
By Thomas Lamb
| Drug Injury Law
Semaglutide NAION lawsuits in 2026 are based on the failure to warn about this serious eye side effect. These court cases seek legal compensation for patients diagnosed with NAION vision loss or blindness. In more detail, lawsuits for Wegovy, Rybelsus, and Ozempic vision loss cases involving semaglutide-associated nonarteritic anterior ischemic optic neuropathy (NAION) are filed against Novo Nordisk, the pharmaceutical company responsible for those three semaglutide-containing GLP-1 drugs.
Open in Who Shared Issue with article?

NAION Linked To Zepbound, Mounjaro, Ozempic, Wegovy: 2026 News Update

|
By Thomas Lamb
| Drug Injury Law
The eye side effect non-arteritic anterior ischemic optic neuropathy (NAION) linked to Zepbound, Mounjaro, Ozempic, Wegovy, and other glucagon-like peptide-1 receptor agonists (GLP-1RA) drugs is the focus of an April 2026 medical study report published online by JAMA Network Open.
Open in Who Shared Issue with article?
See all 83 licensed articles (84 Total)